1.00 / AMA PRA Category 1 CreditTM 1.00 / CE for Nurses 1.00 / CE for Nurse Practitioners
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from AstraZeneca.
Program Description/Statement of Need
As many as one in three patients with cancer suffers from clinically significant pain.1-3 Owing to a broad analgesic spectrum and marked dosing flexibility, opioids have long been the cornerstone of cancer pain therapy.4 Yet the side effects of prescription opioids can limit potential clinical benefits. This is especially true of the most common opioid-related adverse event, constipation, which can be more detrimental to patient function and quality of life than the underlying cancer-related pain.5-8 During this Engaging the PatientTM program, a multidisciplinary faculty panel will review the pathophysiology of opioid-induced constipation (OIC), bowel assessment strategies to help monitor opioid-treated oncology patients, prophylactic laxative treatment regimens, and newer agents that have been approved by the US Food and Drug Administration (FDA) as effective and safe therapies for OIC. Prerecorded patient testimonials and examples of patient-clinician interactions will help shape the interactive faculty discussions. Attendees are sure to complete this educational session with new information and a fresh perspective on managing patients with OIC. ________________________________________________
References 1. Cohen MZ, et al. J Pain Symptom Manage. 2003;25(6):519-527. 2. Goudas LC, et al. Cancer Invest. 2005;23(2):182-190. 3. Dahl JL. J Natl Cancer Inst Monogr. 2004;32:124-126. 4. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Adult Cancer Pain. Version 2.2016. 5. Coyne KS, et al. Clinicoecon Outcomes Res. 2014;6:269-281. 6. Gatti A, Sabato AF. Clin Drug Investig. 2012;32(5):293-301. 7. Holzer P. Expert Opin Investig Drugs. 2007;16(2):181-194. 8. Rao SS. Gastroenterol Clin North Am. 2007;36(3):687-711.
The educational design of this activity addresses the needs of oncology nurses and other clinicians involved in assessing and managing patients with cancer and OIC.
Upon completion of this activity, participants will be better prepared to:
Evaluate baseline and ongoing bowel function in patients with cancer who require opioid-based pain management
Describe the mechanisms of action, published evidence, and practical considerations related to new treatment options for OIC
Recommend prophylactic bowel regimens and newer OIC treatment options when opioid-based treatment regimens are used to treat cancer pain
Communicate with opioid-treated patients with cancer pain to facilitate bowel assessment efforts and shared decision-making about OIC treatment options
Conflict Of Interest Disclosure Policy
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Anthony J. Lembo, MD Associate Professor of Medicine Harvard Medical School Director, GI Motility Laboratory Division of Gastroenterology Beth Israel Deaconess Medical Center Boston, MA
Dr. Lembo discloses the following: Consultant/Independent Contractor: Alkermes plc, Ardelyx, Inc., Forest Laboratories, Inc., Ironwood Pharmaceuticals, Inc., Prometheus Laboratories Inc., Salix Pharmaceuticals, Inc. Grant/Research Support: Prometheus Laboratories Inc.
Nicole M. Ross, MSN, CRNP, AOCNP Advanced Practice Clinician Advanced Oncology Certified Nurse Practitioner Department of Hematology/Oncology Fox Chase Cancer Center Philadelphia, PA
Ms. Ross discloses the following: Honoraria: Eli Lilly and Company, Medscape, Taiho Oncology, Inc.
Michael J. Brennan, MD Medical Director The Pain Center of Fairfield Fairfield, Connecticut Associate Director Chronic Pain and Recovery Center Silver Hill Hospital New Canaan, Connecticut Senior Attending Physician Department of Medicine Bridgeport Hospital Bridgeport, CT
Dr. Brennan discloses the following: Consultant/Independent Contractor: AstraZeneca, Cara Therapeutics Inc., Collegium Pharmaceutical Inc., Depomed, Inc., Progenics Pharmaceuticals, Inc., Purdue Pharma L.P., Teva Pharmaceuticals USA Inc. Honoraria: AstraZeneca, Collegium Pharmaceutical Inc., Depomed, Inc., Progenics Pharmaceuticals, Inc., Purdue Pharma L.P., Teva Pharmaceuticals USA Inc. Stockholder: Cara Therapeutics Inc.
Mihir M. Kamdar, MD Associate Director Division of Palliative Care & and Geriatric Medicine Department of Medicine Director, Cancer Pain Clinic Attending, Palliative Care and Anesthesia Pain Medicine Massachusetts General Hospital Instructor in Medicine Harvard Medical School Boston, MA
Dr. Kamdar discloses the following: Consultant/Independent Contractor: Collegium Pharmaceutical Inc.
Pattie A. Jakel, RN, MN, AOCN Advanced Practice Nurse Advanced Oncology Certified Nurse Solid Tumor Program University of California, Los Angeles Medical Center Santa Monica, CA
Ms. Jakel discloses the following: Speakers Bureau: Genentech, Inc., Merck & Co., Inc.
Planners' and Managers' Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME/CE activity:
Ashley Marostica, RN, MSN, has nothing to disclose. Kristen Delisi has nothing to disclose. Lindsay Borvansky has nothing to disclose. Andrea Funk has nothing to disclose. Laura Gilsdorf has nothing to disclose. Rose O’Connor, PhD, has nothing to disclose. Jim Kappler, PhD, has nothing to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.00 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurse Practitioners
This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 1561024. Activity ID #2417E.
This activity is approved for 1.00 contact hour which includes 0.00 hour of pharmacology.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee and Refund / Cancellation Policy
There is no fee for this educational activity.
In order to receive credit, participants must complete the preactivity questionnaire, post-test, and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.